Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Galapagos NV ADR
(NQ:
GLPG
)
25.48
-0.68 (-2.60%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 8, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
109,070
Open
25.93
Bid (Size)
24.50 (1)
Ask (Size)
26.24 (1)
Prev. Close
26.16
Today's Range
25.47 - 25.95
52wk Range
24.77 - 42.44
Shares Outstanding
N/A
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
FDA Approves Adaptimmune Therapeutics' Engineered Cell Therapy As First For Solid Tumor And New Therapy For Rare Soft Tissue Cancer In Over A Decade
August 02, 2024
FDA approves Adaptimmune Therapeutics' Tecelra for unresectable or metastatic synovial sarcoma, a rare cancer near large joints. Tecelra, the first engineered cell therapy for solid tumors in the U.S.,...
Via
Benzinga
Exposures
Product Safety
GLPG Stock Earnings: Galapagos Beats EPS, Beats Revenue for Q2 2024
August 01, 2024
GLPG stock results show that Galapagos beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024.
Via
InvestorPlace
Performance
YTD
-38.36%
-38.36%
1 Month
-2.93%
-2.93%
3 Month
-11.44%
-11.44%
6 Month
-34.63%
-34.63%
1 Year
-34.26%
-34.26%
More News
Read More
GLPG Stock Earnings: Galapagos Beats EPS, Misses Revenue for Q1 2024
June 25, 2024
Via
InvestorPlace
Adaptimmune and Galapagos Sign Clinical Collaboration Agreement with an Option to Exclusively License Adaptimmune's TCR T-cell Therapy Candidate, uza-cel, in Head & Neck Cancer and Potential Future Solid Tumor Indications
May 30, 2024
Via
Newsfile
Galapagos Downgraded, Pharma Firm Faces Uphill Battle With Slow Pipeline Progress: Analyst
April 01, 2024
Via
Benzinga
8 Analysts Have This to Say About Galapagos
July 17, 2023
Via
Benzinga
Where Galapagos Stands With Analysts
June 12, 2023
Via
Benzinga
JP Morgan Maintains Neutral Rating for Galapagos: Here's What You Need To Know
May 31, 2023
Via
Benzinga
Frontier Medicines Announces Oversubscribed $80 Million Series C Financing to Support Progress of Clinical-Stage Pipeline
February 22, 2024
From
Frontier Medicines
Via
GlobeNewswire
European Drugmaker Galapagos Collaborates With Biotech BridGene Biosciences To Develop Cancer Treatments
January 03, 2024
Via
Benzinga
GLPG Stock Earnings: Galapagos Beats EPS, Beats Revenue for Q3 2023
December 13, 2023
Via
InvestorPlace
Benzinga's Top Ratings Upgrades, Downgrades For May 8, 2023
May 08, 2023
Via
Benzinga
Earnings Outlook For Galapagos
May 03, 2023
Via
Benzinga
Earnings Preview For Galapagos
February 23, 2023
Via
Benzinga
BigCommerce, ContextLogic And Other Big Stocks Moving Lower In Friday's Pre-Market Session
February 24, 2023
Via
Benzinga
Galapagos' Blood Cancer Candidate Shows 100% Objective Response Rate In Relapsed/Refractory Patients
February 10, 2023
Via
Benzinga
Why Galapagos Stock Is Falling Today
February 09, 2023
Via
Benzinga
Twitter Rolls Out 'Blue For Business,' Visa Pitches Auto-Payments On Ethereum Blockchain, Justin Bieber Slams H&M: Today's Top Stories
December 20, 2022
Via
Benzinga
Where Galapagos Stands With Analysts
November 07, 2022
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For January 23, 2023
January 23, 2023
Via
Benzinga
On A Mission As Top European Player, Galapagos Looks For Acquisition Targets
December 20, 2022
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For November 7, 2022
November 07, 2022
Via
Benzinga
After FDA, European Agency Limits Use Of Certain JAK Inhibitors Amid Safety Concerns
October 31, 2022
Via
Benzinga
Expert Ratings for Galapagos
October 13, 2022
Via
Benzinga
3 Biotech Stocks to Sell in October
September 29, 2022
Via
InvestorPlace
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.